Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma

Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma

Summary: EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) have achieved clinical success in lung adenocarcinoma (LUAD). However, tumors often show profound but transient initial response and then gain resistance. We identify transcription factor ZNF263 as being significantly decreased in osimer...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Jiaqi Liang, Guoshu Bi, Qihai Sui, Guangyin Zhao, Huan Zhang, Yunyi Bian, Zhencong Chen, Yiwei Huang, Junjie Xi, Yu Shi, Qun Wang, Cheng Zhan
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Elsevier 2024-02-01
Saila:Cell Reports
Gaiak:
CP: Cancer
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S2211124724000998

Internet

http://www.sciencedirect.com/science/article/pii/S2211124724000998

Antzeko izenburuak